Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jorge F. Quevedo"'
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic b
Autor:
Jorge F. Quevedo, James R. Cerhan, Rhea Kohli, Manish Kohli, Ben Y. Zhang, Douglas W. Mahoney, Brian A. Costello, Shaun M. Riska
Publikováno v:
BJU International. 119:489-495
Objectives To evaluate the prognostic significance of germline variation in candidate genes in patients with castration-resistant prostate cancer (CRPC). Methods Germline DNA was extracted from peripheral blood mononuclear cells of patients with CRPC
Autor:
Hugues Sicotte, Eric D. Wieben, Liewei Wang, Rafael E. Jimenez, Henry C. Pitot, Yeung Ho, Bruce W. Eckloff, Ho Thai, Liguo Wang, Jamie M. Sperger, Joshua M. Lang, David W. Hillman, Haojie Huang, Elizabeth Tseng, Rendong Yang, Jin Jen, Yingming Li, Jamie L. Van Etten, Jorge F. Quevedo, Peter T. Vedell, Manish Kohli, Winston Tan, Christine Henzler, Kevin A. T. Silverstein, Rachel Carlson, Brian A. Costello, Ting Hon, Scott M. Dehm, Tyson A. Clark
Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting AR-V7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc387eee52e6b9a39a1bc34da02bd6c3
https://europepmc.org/articles/PMC5644285/
https://europepmc.org/articles/PMC5644285/
Autor:
Judith S. Kaur, Vera J. Suman, Edward T. Creagan, Jorge F. Quevedo, Svetomir N. Markovic, Wendy K. Nevala, Robert R. McWilliams, Matthew S. Block, Lisa A. Kottschade
Publikováno v:
Melanoma Research. 21:438-445
Thus far, peptide vaccines used to stimulate tumor-specific immune responses in patients with melanoma have been largely unsuccessful. Granulocyte-macrophage colony-stimulating factor and interleukin-2 are immune-potentiating cytokines that have impr